2-(4-氟苄基)苯酚 | 401-30-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(4-氟苄基)苯酚
• 英文名称: 2-(4-fluorobenzyl)phenol
• 英文别名: 2-[(4-fluorophenyl)methyl]phenol
• CAS: 401-30-9
• 化学式: C₁₃H₁₁FO
• 分子量: 202.228
• InChiKey: XMPYZRODFDIJPK-UHFFFAOYSA-N

物化性质

• 沸点：
  136-141 °C(Press: 3 Torr)
• 密度：
  1.179±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(4-氟苄基)苯酚 生成 N-hydroxy-N-[4-(5-(4-(4-fluorophenylmethyl)phenoxy)-furan-2-yl)-3-butyn-2-yl]urea
  参考文献：
  名称：

  Acetylene derivatives having lipoxygenase inhibitory activity

  摘要：

  结构为##STR1##的化合物，其中p和q为零或一，但不能同时相同，M是一种药用可接受的阳离子或代谢可裂解基团，B是一个价键或直链或支链烷基基团，R是烷基、环烷基或--NR.sup.1 R.sup.2，其中R.sup.1和R.sup.2是氢、烷基、环烷基或烷酰基，A是可选择取代的碳环芳基、呋喃基、苯并[b]呋喃基、噻吩基或苯并[b]噻吩基，是脂氧合酶酶的强效抑制剂，从而抑制白三烯的生物合成。这些化合物在治疗或缓解过敏和炎症性疾病状态中很有用。

  公开号：

  US05476873A1
• 作为产物：
  描述：

  2-苄氧基溴苯 在 盐酸 、 正丁基锂 、 氢气 、 palladium(II) hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 正己烷 、 水 、 乙酸乙酯 为溶剂， 反应 17.33h， 生成 2-(4-氟苄基)苯酚
  参考文献：
  名称：

  5a-Carba-β-d-glucopyranose derivatives as novel sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes

  摘要：

  5a-Carba-beta-D-glucopyranose derivatives were synthesized and identified as novel SGLT2-selective inhibitors. These inhibitors exhibited potent SGLT2 inhibition with high selectivity over SGLT1. Among the tested compounds, 6f indicated the most potent hSGLT2 inhibition and the highest selectivity over hSGLT1. Moreover, the pharmacokinetics data also showed that 6h, which had the same aglycon structure as sergliflozin-active (3-active), had a threefold longer half-life time (T(1/2)) than sergliflozin (3) with a high distribution volume in db/db mice. Subsequently, 6h lowered blood glucose levels as much as 3 and showed longer hypoglycemic action than 3 in db/db mice. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.08.005

文献信息

• Metal-Free C–O Bond Functionalization: Catalytic Intramolecular and Intermolecular Benzylation of Arenes
  作者：Luis Bering、Kirujan Jeyakumar、Andrey P. Antonchick

  DOI：10.1021/acs.orglett.8b01495

  日期：2018.7.6

  conditions enabled a catalytic and metal-free Friedel–Crafts alkylation reaction with benzylic alcohols, producing water as the stoichiometric byproduct. A comprehensive scope (>50 examples) for both approaches and application in drug synthesis were demonstrated. Mechanistic studies suggest a Lewis acid-based mechanism for the metal-free Friedel–Crafts reaction.

  描述了使用硝鎓盐作为催化剂的苄基苯基醚的无金属催化的分子内重排。优化的反应条件使苄基醇能够进行无金属催化的Friedel-Crafts烷基化反应，从而产生水作为化学计量副产物。展示了方法和在药物合成中的应用的综合范围（> 50个示例）。机理研究表明，路易斯酸基机理可用于无金属的Friedel-Crafts反应。
• Novel Phosphinic Acid-Containing Thyromimetics
  申请人：Erion Mark D.

  公开号：US20090028925A1

  公开（公告）日：2009-01-29

  The present invention relates to compounds of phosphonic acid-containing T3 mimetics and monoesters thereof, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndrome x and diabetes.

  本发明涉及含有磷酸基T3拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟
• [EN] NOVEL THYROMIMETICS<br/>[FR] NOUVEAUX THYROMIMÉTIQUES
  申请人：AUTOBAHN THERAPEUTICS INC

  公开号：WO2020180624A1

  公开（公告）日：2020-09-10

  Compounds are provided having the structure of Formula (I): or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein A, X1, X2, Q, R1, R2 and n are as defined herein. Such compounds function as thyromimetics and have utility for treating diseases such as neurodegenerative disorders and fibrotic diseases. Pharmaceutical compositions containing such compounds are also provided, as are methods of their use and preparation.

  提供具有以下结构的化合物（I）的结构：或其药学上可接受的异构体、拉氏体、水合物、溶剂合物、同位素或盐，其中A、X1、X2、Q、R1、R2和n如本文所定义。这些化合物作为甲状腺类似物发挥作用，并可用于治疗神经退行性疾病和纤维化疾病等疾病。还提供含有这些化合物的药物组合物，以及它们的使用和制备方法。
• [EN] THYROMIMETICS<br/>[FR] THYROMIMÉTIQUES
  申请人：AUTOBAHN THERAPEUTICS INC

  公开号：WO2021257804A1

  公开（公告）日：2021-12-23

  Disclosed herein are thyromimetic compounds having utility for treating diseases such as neurodegenerative disorders and fibrotic diseases. Pharmaceutical compositions containing such compounds are also provided, as are methods of their preparation.

  本文披露了具有治疗神经退行性疾病和纤维化疾病等疾病效用的甲状腺模拟化合物。还提供了含有这些化合物的药物组合物以及它们的制备方法。
• Novel Phosphorus-Containing Thyromimetics
  申请人：Erion Mark D.

  公开号：US20100081634A1

  公开（公告）日：2010-04-01

  The present invention relates to compounds of phosphonic acid-containing T3 mimetics and monoesters thereof, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndrome x and diabetes.

  本发明涉及含有膦酸的T3模拟物化合物及其单酯、立体异构体、药学上可接受的盐、共晶体和前药及其药学上可接受的盐和共晶体，以及它们的制备和用于预防和/或治疗代谢性疾病，如肥胖症、NASH、高胆固醇血症和高脂血症，以及相关疾病，如动脉粥样硬化、冠心病、糖耐量受损、代谢综合征X和糖尿病的用途。